Biotech giant CSL crashes despite 20 percent profit growth driven by core immunoglobulin business
CSL forecasts double-digit earnings growth this year, supported by its key immunoglobulin business. However, the biotech giant warned that sales growth would be rather low given the difficult market conditions for its vaccines.